Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • How I Treat丨Prof. Fengkui Zhang: My Approach to Treating Severe Aplastic Anemia

    Severe aplastic anemia (AA) remains a significant therapeutic challenge despite progress in its diagnosis and treatment. Issues such as difficulty in donor matching, side effects of immunosuppressive therapy (IST), and suboptimal hematologic responses demand continued exploration of innovative solutions. Prof. Fengkui Zhang of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical…

    2024.12.03
  • 2024 Great Wall Hematology Forum丨Prof. Wenming Chen: Integrating Fundamentals and Clinical Practice to Foster Young Talent

    On November 15–16, 2024, the “Annual Meeting of the Hematology Committee of the Chinese Medical Education Association—Great Wall Hematology Forum” was successfully held in Beijing. This conference brought together leading experts in hematology to discuss advancements in the diagnosis and treatment of hematological diseases, delve into the latest research findings, and explore the future direction…

    2024.12.03
  • SIBCS 2024 | A Sneak Peek at Key Updates in the 2025 Edition of the “CBCS Little Red Book” from Top Experts

    The expert voting on key issues for the 2025 edition of the Guidelines and Standards for Breast Cancer Diagnosis and Treatment (Essential Version), also known as the CBCS Little Red Book, organized by the Chinese Anti-Cancer Association and the Chinese Medical Association’s Oncology Branch, has concluded. The new version is on the horizon! Oncology Frontier…

    2024.12.03
  • Dr.Hong You and Dr.Wei Chen’s Team Proliferative T Cell Subpopulations in the Liver Promote Fibrosis Reversal in CHB Patients After Antiviral Therapy

    Research Background and Objectives CHB liver fibrosis is a pathological condition resulting from imbalanced extracellular matrix deposition due to HBV-induced liver damage and repair. This condition can progress to cirrhosis…

    2024.12.03
  • AASLD’s Chinese Impact: Dr. Liang Peng’s Team Achieves Multiple Research Milestones in Chronic Hepatitis B and Related Liver Failure

    Study 1: Personalized Nutritional Support for HBV-ACLF Patients at Nutritional Risk: Preliminary Findings from a Randomized Controlled Trial Authors: Zhipeng Li, Peipei Wang, Wenxiong Xu, Chan Xie, Liang Peng Malnutrition…

    2024.12.03
  • AASLD 2024 | Nadege Pelletier: Exploring new hope for innovative immunotherapy for chronic hepatitis B

    Hepatology Digest: Thank you for joining us. Could you start by introducing yourself and sharing the focus of Barinthus Biotherapeutics? Nadege Pelletier: Of course, thank you. My name is Nadege…

    2024.12.03
  • Dr. Hua Zhong and Dr. Baohui Han: Docetaxel Combined with Plinabulin in Second-Line Treatment for Mutation-Negative Advanced NSCLC Patients

    Modern advancements in oncology have introduced various breakthrough treatment options for lung cancer, which is now one of the most rapidly evolving solid tumors. To help clinicians stay updated on key advancements in this field, Oncology Frontier has partnered with Dr. Hua Zhong and Dr. Baohui Han of the Department of Respiratory and Critical Care…

    2024.12.02
  • Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West China Experience

    Upper tract urothelial carcinoma (UTUC), encompassing renal pelvic and ureteral cancers, is relatively rare, with unique characteristics in the Chinese population, such as distinct disease features and molecular biology profiles. The 8th West China Uro-Oncology Tianfu Academic Conference, recently held in Chengdu, provided a platform to discuss how to better address the challenges in UTUC…

    2024.12.02
«previous next»
Recent Posts
  • Yixian Breast Cancer Conference 2025 | Professor Chang Gong: Stratified Optimization and Precision Escalation/De-Escalation in HER2-Positive Breast Cancer
  • 2025 Yixian Breast Cancer Conference | Professor Kun Wang: Immunotherapy, Chemotherapy, and ADCs Advancing in Parallel to Drive Continued Breakthroughs in Triple-Negative Breast Cancer Outcomes
  • Northern Breast Cancer Forum 2026 | Professor Peng Yuan: Driving Clinical Transformation Through “Three New Forces” and Anticipating Key Updates in the 2026 CSCO Breast Cancer Guidelines
  • Professor Yongsheng Wang: What Has Changed—and What Remains—in Breast Cancer Surgery?
  • CASH 2026 | Science Knows No Borders: A Video Dialogue with International Forum Chair Professor Toshio Suda
Recent Comments
    Archives
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top